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Abstract: N-glycosylation has been shown to affect the pharmacokinetic properties of several classes
of biologics, including monoclonal antibodies, blood factors, and lysosomal enzymes. In the last two
decades, N-glycan engineering has been employed to achieve a N-glycosylation profile that is either
more consistent or aligned with a specific improved activity (i.e., effector function or serum half-life).
In particular, attention has focused on engineering processes in vivo or in vitro to alter the structure
of the N-glycosylation of the Fc region of anti-cancer monoclonal antibodies in order to increase
antibody-dependent cell-mediated cytotoxicity (ADCC). Here, we applied the mannosidase I inhibitor
kifunensine to the Nicotiana benthamiana transient expression platform to produce an afucosylated
anti-CD20 antibody (rituximab). We determined the optimal concentration of kifunensine used in the
infiltration solution, 0.375 µM, which was sufficient to produce exclusively oligomannose glycoforms,
at a concentration 14 times lower than previously published levels. The resulting afucosylated
rituximab revealed a 14-fold increase in ADCC activity targeting the lymphoma cell line Wil2-S when
compared with rituximab produced in the absence of kifunensine. When applied to the cost-effective
and scalable N. benthamiana transient expression platform, the use of kifunensine allows simple
in-process glycan engineering without the need for transgenic hosts.
Keywords: ADCC; glycosylation; kifunensine; plant made pharmaceuticals; monoclonal antibody
1. Introduction
Monoclonal antibodies (mAbs) represent the fastest growing class of therapeutics [1,2] and have
been especially beneficial in the treatment of cancer [3]. Since the approval of the first anti-cancer
monoclonal antibody in 1986 [4], several innovations have improved the potency of monoclonal
antibodies used in immunotherapies that offer increased drug efficiency and/or lower drug dosage for
a specific treatment. Among them, glycan engineering of the oligosaccharides attached to Asn297 of the
Fc region of the heavy chain has been shown to affect antibody-dependent cell-mediated cytotoxicity
(ADCC), complement dependent cytotoxicity (CDC), and binding to the neonatal Fc receptor,
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FcRn [5–7]. Specific oligosaccharides influence the affinity of the antibody Fc domain to Fc receptor
present on effector cells resulting in altered biological functions. For example, the removal of terminal
galactose residues on mammalian cell-derived antibodies lowered C1q binding [8,9], while ADCC
activity is almost completely dependent on the presence or absence of fucose residues bound to the
glycosylation core [10–12]. Several approaches have been employed to manufacture a monoclonal
antibody with a decreased or absent core fucosylation. One strategy is to use cell lines or organisms
with modified glycosylation pathways [13–16]. The alteration of the expression of key enzymes
in the host glycosylation pathway such as the mammalian α1,6-fucosyltransferase [15], the plant
α1,3-fucosyltransferase [17–21], the GDP (guanosine 5’-diphosphate)-mannose 4,6-dehydratase [11,22],
or the β1,4-N-Acetylglucosaminyltransferase III [14,23] led to afucosylated antibodies with improved
anti-tumor activity. This led to the approval of mogamulizumab (POTELIGIO®, Kyowa Hakko
Kirin) [24] and obinutuzumab (Gazyva®, Roche) [25] in 2012 and 2013, respectively, both produced
in glycoengineered mammalian cell lines. Another approach to alter the antibody glycosylation
profile is to modify the culture conditions of the host cells by adjusting the growth environment [26]
or supplementing the media with inhibitors of enzymes in the glycosylation pathway such as
N-butyldeoxynojirimycin (NB-DNJ), mannostatin A, swainsonine, or kifunensine [27–31]. Kifunensine
from the actinomycete Kitasatosporia kifunense 9482 inhibits class I α-mannosidases and blocks N-glycan
synthesis at the Man8GlcNAc2 (Man8) or Man9GlcNAc2 (Man9) stage before the core fucose is
added [28,32]. In mammalian cell culture, kifunensine was successfully employed to produce protein
with >90% high-mannose content [28,29,33,34]. This effect was similar across many different proteins
including antibodies, suggesting that this simple treatment could be applied broadly. Compared to
other α-mannosidase I inhibitors, kifunensine is highly effective on mammalian cell culture without
significantly affecting cell growth or protein yield, even at concentrations as low as 100 ng/mL
culture [29,33,34]. Similar to mammalian cell studies, kifunensine was used in conjunction with the
Nicotiana benthamiana transient protein expression systems to produce proteins with >98% afucosylated
high-mannose glycans [35–37]. In plants, the non-human α1,3-fucose and β1,2-xylose residues are
commonly added in the Golgi apparatus after mannose trimming by mannosidases in the endoplasmic
reticulum. Upon kifunensine treatment, addition of α1,3-fucose and β1,2-xylose residues were not
observed on the Man3 to Man9 structures [35,37]. However, the amount of kifunensine used in these
studies was at or above 1.16 µg/mL (5 µM) [35,37], which significantly increases production costs at
the manufacturing scale.
Kifunensine is currently being used to manufacture a recombinant glucocerebrosidase in
HT1080 fibrosarcoma cells (Velaglucerase alpha, Shire Plc.) to treat type 1 Gaucher disease [38].
The process of Velaglucerase alpha was design to modify the glycosylation profile of the protein
toward oligomannose N-glycans to improve mannose-receptor mediated uptake of the drug into
macrophages, the target cells [39]. Here, we determined the optimal concentration of kifunensine
and demonstrate that kifunensine addition at a concentration of 0.375 µM (87 ng/mL) in the
Agrobacterium infiltration solution of N. benthamiana plants during the vacuum infiltration process
allows the production of exclusively high-mannose recombinant proteins. The anti-CD20 monoclonal
antibody rituximab, approved for the treatment of non-Hodgkin’s lymphoma (NHL) [40], was selected
to evaluate the effectiveness of kifunensine for the production of an anti-cancer antibody with
enhanced antibody-dependent cell mediated cytotoxicity (ADCC). ADCC efficacy of rituximab is
inversely correlated with the content of core fucose [41,42], suggesting that a rituximab variant with
altered glycosylation would lower dosing requirements. More importantly, we demonstrate that
afucosylated high-mannose decorated antibody, derived from the treated plants, exhibits increased
ADCC effector function, as compared with rituximab derived from non-treated plants. The increased
ADCC activity was verified using effector cells carrying both FcγRIIIa-V158 and FcγRIIIa-F158
allotypes. Several strategies could be implemented to modulate the plant-specific glycans: (i) Protein
containment in the Endoplasmic Reticulum (ER) using specific signal sequences (i.e., SEKDEL sequence:
Ser-Glu-Lys-Asp-Glu-Leu) [43], (ii) knockdown of fucosyltransferase and xylosyltransferase enzymes
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in N. benthamiana with RNA interference (RNAi) technology [18], (iii) knockout of fucosyltransferase
and xylosyltransferase enzymes in N. benthamiana using gene editing [44], and (iv) replacement of plant
glycans with human glycans through glyco-remodeling [45]. Gene editing using sequence-specific
transcription-activator-like effector nucleases (TALENs) was only partially effective [44], while the
use of transgenic knockdown lines at manufacturing require more exigent containment and cleaning
procedures. Our approach eliminates the need for modification of the primary sequence or the use
of transgenic, regulated material for manufacturing. Combined with the scalability [46] and low
manufacturing cost associated with the N. benthamiana transient expression system [47], this method
represents an excellent alternative to the use of either glycoengineered or kifunensine-treated
mammalian cell lines for the production of afucosylated anti-cancer antibody.
2. Results
2.1. Kifunensine Treatment of N. benthamiana did not Impede Rituximab Expression
Rituximab transiently expressed in N. benthamiana typically presents complex glycans of
GlcNAc2(Xyl)Man3(Fuc)GlcNAc2 on Asn297 of the heavy chain (Figure 1A).
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(www.functionalglycomics.org). Blue squares ‐N‐acetylglucosamine; Green circles ‐Mannose; Orange 
Star‐ Xylose;  and Red  Triangle‐Fucose.  (B)  Phenotype  of N.  benthamiana  plants  infiltrated  under 
vacuum with Agrobacterium suspension ± kifunensine. Each experimental group received different 
concentrations  of  kifunensine  in  the  Agrobacterium  infiltration  solution  and  concentrations  are 
indicated on top of each treatment image. (C) Quantification of rituximab in crude protein extracts 
using Biolayer interferometry (BLItz®, ForteBio). Expression levels of rituximab in 7 dpi plant extracts 
Figure 1. Effect of kifunensine on plant-made rituximab. (A) Schematic representation of Immunoglobulin
G 1 (IgG1) glycosylation. Complex-type plant glycans (black dotted lines) formed in the absence
of kifunensine (black arrow) transform d into Oligomannose-type glycans (red dotted lines) in the
presence of kifunensine (red arrow). The oligosaccharide structures are shown in the symbolic
depiction suggested by the Consortium of Functional Glyco ics (www.functionalglycomics.org).
Blue squares -N-acetylgluc s m ne; Green circles -Mannose; Orange St r- Xylose; an Red Triangle-Fucose.
(B) Phenotype of N. benthamiana plants infiltrated under vacuum with Agrobacterium suspension ±
kifunensine. Each experimental group received different concentrations of kifunensine in the Agrobacterium
infiltration solution and concentrations are indicated on top of each treatment image. (C) Quantification
of rituximab in crude protein extracts using Biolayer interferometry (BLItz®, ForteBio). Expression levels
of rituximab in 7 dpi plant extracts with (orange) and without (green) kifinensine are reported in mg
rituximab/kg fresh weight (FW). Error bars represent standard deviations of duplicated expression
measurements, where n = 3. (D) SDS-PAGE (sodium dodecyl sulfate Polyacrylamide gel electrophoresis)
analysis of purified rituximab samples under reduced and non-reduced conditions. Rituxan, plant-made
rituximab with no kifunensine, 0.25 µM kifunensine, 2.5 µM kifunensine, and 5 µM kifunensine were
separated on a 4–12% Bis-Tris gel along with Novex sharp pre-stained protein standard.
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We have hypothesized that a treatment with kifunensine would inhibit trimming of mannose
residues in the endoplasmic reticulum (ER), subsequently preventing the addition of α1,3-fucose
and β1,2-xylose residues on the polysaccharide core (Figure 1A). To do so, 60 plants per conditions
were vacuum infiltrated in a solution of Agrobacteria with or without kifunensine, ranging from 0 to
5 µM (0 µg/mL to 1.16 µg/mL). Visual observation of infiltrated plants from three to seven days post
infiltration (dpi) revealed no noticeable phenotypic or morphological differences between treated and
untreated control plants (Figure 1B). All leave and stems were collected from each infiltration (~250 g
plant biomass) and pooled for protein extraction and purification. Rituximab expression levels were
quantified at 7 dpi and revealed a low to moderate increase (up to 34%) in antibody expression between
untreated and treated plants, with the average rituximab expression level ranging from 288 mg/kg to
385 mg/kg whole plant fresh weight (FW) in treated plants, compared to 287 mg/kg whole plant FW
in untreated plants (Figure 1C). These observations demonstrated that the kifunensine treatments were
not detrimental to plant growth or protein expression. To evaluate the effect of kifunensine treatments
on the integrity and assembly of rituximab, SDS-PAGE analysis was carried out under reduced and
non-reduced conditions. As illustrated in Figure 1D, rituximab derived from kifunensine treated and
untreated conditions appeared intact and fully assembled. Non-reduced rituximab migrated at the
expected molecular weight (MW) of ~145 kDa, while the reduced heavy and light chains migrated at
the expected MW of ~50 kDa and ~25 kDa, respectively (Figure 1D). Infiltration experiments were run
in duplicates.
2.2. A Concentration of 0.375 µM of Kifunensine is Sufficient to Produce Rituximab with Afucosylated,
Oligomannose-Type Glycoforms Exclusively
The N-glycosylation profiles of purified rituximab expressed in N. benthamiana were evaluated by
LC-MS/MS (Liquid Chromatography-Mass Spectrometry) analysis (Figure 2).
The major glycoforms were compared based on the relative intensity of the Asn297 glycopeptide
masses identified by LC-MS/MS. We first established the glycoform distribution of rituximab derived
from untreated plants (Figure 2; 0 µM kifunensine). As previously described in the literature,
this plant-derived rituximab control exhibited primarily complex-type N-glycans [48], with the most
abundant N-glycan structure being GlcNAc2(Xyl)Man3(Fuc)GlcNAc2 (Figure 3).
On the other hand, there were significant differences in rituximab N-glycan profiles between
untreated and treated samples. Complete conversion of plant complex glycans to oligomannose-type
glycans was observed when N. benthamiana plants were infiltrated with ‘higher range’ and ‘medium
range’ concentrations of kifunensine (from 5 µM to 0.375 µM). The GlcNAc2Man9 (Man9) and
GlcNAc2Man8 (Man8) were the major glycoforms observed (Figure 2; 0.25 to 5 µM kifunensine)
with Man9 being the most abundant. In fact, the same oligomannose-type glycoform distribution was
observed whether 0.375 µM or higher kifunensine concentration was used, indicating that 0.375 µM is
sufficient to provide homogeneous rituximab with oligomannose-type glycans (Figure 3). When lower
concentrations of kifunensine were used, a mixture of oligomannose, hybrid, and complex glycans
was detected (Figure 2; 0.25 µM kifunensine). For instance, the glycosylation profile of rituximab
from plants treated with 0.25 µM contained more than ~48% hybrid/complex glycan modifications
(GnGn, GnGnX, and GnGnXF) and ~52% oligomannose (Man6, Man7, Man8, and Man9) glycosylation
(Figure 3). Importantly, no α1,3-fucose or β1,2-xylose residues were detected in rituximab derived
from plants treated with ≥0.375 µM kifunensine.
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LC-MS (Liquid Chromatography-Mass Spectrometry) glycopeptide profiling of rituximab expressed in
control and kifunensine treated plants. The distribution of glycoforms in each sample is illustrated
and kifunensine concentrations are indicated on each image. Blue squares -N-acetylglucosamine;
Green circles -Mannose; Orange Star- Xylose; and Red Triangle-Fucose.
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2.3. Rituximab Decorated with Oligomannose Residues Binds Target CD20 as Efficiently as Rituxan®
The mo e of action of rituximab is charact ized first by binding to the tum r cell surface an igen
CD20 present of lymphoma cells before cell cytotoxicity is induced. T us, to confirm that rituximab
derived from kifunensine-treat d plants binds CD20, a flow cytometry analysis using the hum B
cell line Wil2-S w s performed. Rituximab sa ples purified from plants treated with 0, 0.25, 0.375,
1.25, 2.5, and 5 µM of kif ensine was compared to Rituxa ® for he proteins’ ability to bind CD20
on Wil2-S cells. This analysis eveal d no difference i the binding ffinity of rituximab derived from
plants treated with 5 µM or 0.25 µM kifunensine as compared with Rituxan® (Figure 4). In all antibody
independent assays and isotype controls, no CD20 binding signal was observed.
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Figure 4. CD20 binding assay of rituximab treated t kifunensine 5 µM, 0.25 µM and untreated
controls with Flow Cytometry analysis. Plant-made rituxi ab was used at concentrations of 50 nM,
25 nM and 12.5 nM. Antibodies bound to CD20 on Wil2-S were detected with goat anti-human IgG
polyclonal antibodies conjugated with Fluorescein isothiocyanate (FITC). Median Fluorescence intensity
(MFI) was derived from the median value of the fluorescence histogram.
2.4. Effect of Kifunensine on Biological Activity of Rituximab Produced in N. benthamiana
Rituximab samples purified from plants treated with 0, 0.25, 0.375, 1.25, 2.5, and 5 µM of
kifunensine, as well as a commercially available rituximab (Rituxan®) were assessed for their ability to
generate in vitro ADCC activity against the Wil2-S human B cell line using modified Jurkat effector cells
expressing either the F158 or V158 variant of the Fc receptor RIIIa (FcγRIIIa or CD16a). In the human
population, FcγRIIIa polymorphism is observed at amino acid 158 [Valine (V)/Phenylalanine (F)] of
the FcγRIIIa with the V158 allotype exhibiting a hig er affinity for IgG1. The relative ADC activity
between the samples was represented by non-linear regression activity curves comparing normalized
ADCC activities (as measured by induced florescence) to rituximab concentrations (Figure 5A,B).
A robust, dose-dependent reporter signal was produced when Wil2-S cells were co-incubated with
either FcγRIIIa-V158 (Figure 5A) or FcγRIIIa-F158 (Figure 5B) effector cells and rituximab. The 50%
effective concentrations (EC50) calculated from these curves were directly compared between samples
to evaluate the efficacy of each antibody variant. Compared to rituximab from untreated plants and
mammalian cell derived Rituxan®, rituximab derived from plants treated with ≥0.25 µM kifunensine
induced significantly greater ADCC activity with both FcγRIIIa-V158 (Figure 5C) and FcγRIIIa-F158
(Figure 5D) effector cell variants. The ADCC activity of rituximab with oligomannose-type glycans
was increased by 14-fold and 9.5-fold when using V158 and F158 variant effector cells, respectively
(Figure 5C,D), as compared with Rituxan®. Interestingly, the increase in ADCC activity from rituximab
derived from plants treated with 0.25 µM kifunensine (Figure 5) was found to be intermediate between
the non-treated rituximab and rituximab derived from plants treated with ≥0.25 µM kifunensine
(Figure 5C,D). This may be attributed to a similar intermediate content in α1,3-fucose on this rituximab
sample compared to the other rituximab samples. In all antibody independent assays (AICC), no signal
was observed in the absence of antibody.
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Jurkat cells. The effector cell: target cell ratio was 10:1. Values are expressed as normalized RLUs (A,B) 
and represent the mean ± Standard Deviation (SD). for triplicate analyses. Summary of ADCC activity 
represented as EC50 values. The horizontal dotted defines 100% and 50% value (C,D), normalized to 
the control 0uM kifunensine control value,  indicating relative activity. The error bars of each EC50 
value correspond to the standard error of the mean. 
A robust, dose‐dependent reporter signal was produced when Wil2‐S cells were co‐incubated 
with either FcγRIIIa‐V158 (Figure 5A) or FcγRIIIa‐F158 (Figure 5B) effector cells and rituximab. The 
50% effective concentrations  (EC50) calculated  from  these curves were directly compared between 
samples  to evaluate  the efficacy of each antibody variant. Compared  to rituximab  from untreated 
plants and mammalian cell derived Rituxan®, rituximab derived from plants treated with ≥0.25 μM 
kifunensine  induced significantly greater ADCC activity with both FcγRIIIa‐V158 (Figure 5C) and 
FcγRIIIa‐F158 (Figure 5D) effector cell variants. The ADCC activity of rituximab with oligomannose‐
type glycans was increased by 14‐fold and 9.5‐fold when using V158 and F158 variant effector cells, 
respectively (Figure 5C,D), as compared with Rituxan®. Interestingly, the increase in ADCC activity 
from rituximab derived  from plants  treated with 0.25 μM kifunensine  (Figure 5) was found  to be 
intermediate between  the non‐treated  rituximab  and  rituximab derived  from plants  treated with 
Figure 5. Antibody-dependent cell-mediated cytotoxicity of rituximab samples expres ed in the
presence or absence of kifunensine. As ay was performed using Wil2-S target cells along with either
high affinity V/V 158 FcγRIIIa variant (A,C) or low affinity F/F 158 FcγRI Ia variant (B,D) engine red
Jurkat cells. The ffector cell: target cell ratio was 10:1. Values are expres ed as normalized RLUs (A,B)
and represent the mean ± Standard Deviation (SD). for triplicate analyses. Summary of ADC activity
represented as EC50 values. The horizontal dotted defines 10 % and 50% value (C,D), normalized to
the control 0 uM kifunensine control value, indicating relative activity. The error bars of each EC50
value correspond to the standard error of the mean.
3. Discussion
3.1. Kifunensine Treatment Is Well Tolerated During Expression of Rituximab in N. benthamiana
To date, several inhibitors of the N-glycosylation pathway have been used to modulate
the glycosylation profiles of recombinant proteins. Among them, kifunensine, an inhibitor of
class I mannosidases, acts early in the N-glycosylation processing by blocking the trimming
of Man9 oligosaccharides to Man5. In comparison, application of swainsonine, an inhibitor of
class II mannosidases, leads to the formation of a more heterogeneous population of N-glycans
with fucose-containing hybrid structures as well as oligomannose structures [49,50]. dditionally,
kifunensine has been shown to be very efficient at low concentrations, as compared with swainsonine,
thus becoming a good candidate as a medium supplement for alternation of host N-glycosylation
pathways. While it has been used in mammalian cells since 1990 [28], it was only recently applied in
the plant expression systems [35–37].
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In this study, we have investigated the use of kifunensine in a plant expression platform
that is established for large-scale manufacturing for recombinant protein [46]. More specifically,
we evaluated the concentration of kifunensine sufficient for the production of an afucosylated
rituximab with enhanced biological activity. The vacuum infiltration of plants in a solution containing
Agrobacterium culture supplemented with kifunensine at a concentration varying from 0.0625 µM
to 5 µM did not affect the seven-day post-infiltration growth of the plants or the expression of
rituximab. In fact, the expression of rituximab was slightly higher from kifunensine-treated plants.
Similar tolerance to kifunensine treatment has also been described for the expression of antibodies
in Chinese Hamster Ovary (CHO) cells [29,33]. However, it has been reported in one instance that
kifunensine treatment of N. benthamiana plants via the growth medium led to a decrease in expression
of a recombinant protein [35]. When applied during plant vacuum infiltration in the Agroinfiltration
solution, kifunensine enters the interstitial spaces of the leaf tissue in contact with the host cells where
recombinant protein expression occurs, rather than through uptake via the root system. The positive
impact of infiltrated kifunensine on host cell tolerance and protein production may be due to its
suppressing effects on the ER-associated degradation pathway [51] where proteins with trimmed
oligomannose glycans may be degraded if the polysaccharide chain is not further processed or proteins
transported to the Golgi apparatus [52,53].
3.2. Kifunensine Has a Strong Effect on the Plant N-glycosylation Machinery, even at Low Concentration
Kifunensine treatment during the agroinfiltration ultimately results in protein afucosylation as
it stops mannose trimming in the endoplasmic reticulum, yielding Man5-Man9 N-glycan structures.
When delivered in this fashion, a minimum concentration of 0.375 µM kifunensine was sufficient
to generate rituximab harboring only oligomannose glycan structures lacking fucose residues.
In agreement with reports using mammalian cell cultures [29,33], the minimum required kifunensine
concentration to generate antibody devoid of fucose residues in N. benthamiana falls somewhere
between 0.25 and 0.375 µM (58 and 87 ng/mL). Kifunensine has the practical advantage of being
active at 2-to-4-fold-lower concentrations than other inhibitors of the glycosylation pathway (e.g.,
swainsonine or N-butyldeoxynojirimycin) making it more cost-effective. Moreover, as described here
and in mammalian cell cultures, treatments with kifunensine leads to a highly homogeneous product,
with ultimately no formation of core-fucosylated hybrid structures [29,33–35,37].
3.3. Kifunensine Represents a Cost-Effective Method to Produced Biobetter Anti-Cancer Antibodies
Proteins produced with glycan-engineering technologies not only lack potentially immunogenic
plant-specific glycoforms, but also provide enhanced effector function. The in vitro bioassay described
in this study demonstrated enhanced ADCC activity from rituximab containing high-mannose
glycoforms. It is expected that the reason for this increased ADCC activity lies in the absence of
fucose residues on the glycosylation core rather than the high content of mannose residues, as many
studies have reported the effect of afucosylation on the ADCC activity of anti-cancer antibodies [54]
including rituximab [10,20,55,56]. In fact, similar ADCC results were obtained with antibodies
derived from CHO cell cultures treated with kifunensine [33,34]. It is important to note that ADCC
activity was linearly proportional to the relative abundance of oligomannose glycoforms. This was
particularly evident with ‘low-range’ concentrations of kifunensine applied, which generated a mixture
of complex, hybrid, and oligomannose structures. With rituximab derived from a treatment of 0.25 µM
kifunensine, generating a relatively small increase (24%) of oligomannose glycoforms, there was
a significant but lower increase in ADCC activity (6.7-fold and 2-fold increase in ADCC activity
using the FcγRIIIa-V158 and FcγRIIIa-F158 effector cell variants, respectively) (Figure 5). Importantly,
plant-derived high-mannose rituximab glycoforms exhibited the same affinity for CD20 as Rituxan®,
the commercial standard. Thus, the kifunensine treatment does not affect the paratope conformation of
the plant-derived antibody. As the glycosylation profile of an anti-cancer antibody is correlated to its
biological activity, it is therefore considered as a critical quality attribute that needs to be maintained
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during the manufacturing process [57]. To that end, the glycosylation profile of kifunensine-treated
antibodies is homogeneous, consistent, and easy to control at scale, which represent a significant
advantage for this technology. There are reports that antibodies carrying high mannose glycans have a
shorter serum half-life, as compared with other glycoforms [33,58,59]. However, other pharmacokinetic
studies with afucosylated high mannose antibodies indicated no impact on clearance [29,34,60]. Thus,
the pharmacokinetics property of any antibody will have to be evaluated based on its biological activity,
the target indication, and dosage regimen.
In conclusion, the application of kifunensine during transient agroinfiltration of the N. benthamiana
host leverages the scalability and cost-effectiveness of the plant expression platform for the production
of biobetter anti-cancer antibodies. First, the scale-up of rituximab expression (up to 150 kg of
plant biomass but without kifunensine) was also demonstrated at the iBio CDMO facility using
manufacturing procedures without affecting the expression or product quality. Second, using the
process model described by Holtz et al. 2015 [46], and the findings from this study (a kifunensine
concentration of 0.375 µM), the cost of cGMP (current Good Manufacturing Practice)-grade kifunensine
to produce high-mannose, afucosylated antibodies at manufacturing scale (~100 kg/year of rituximab)
was estimated to be less than $0.80/g of antibody produced. Thus, kifunensine can be incorporated
into already established manufacturing protocols without affecting production cost significantly.
Further studies will focus on determining how long the inhibition effect of kifunensine lasts during
and after the plant infiltration process. This attempt to increase anti-cancer efficacy of recombinant
antibodies through in-process glycan engineering represents a promising alternative to meet unmet
medical needs.
4. Materials and Methods
4.1. Construction of Heavy Chain and Light Chain Expression Vectors
The genetic sequence of rituximab heavy and light chains was obtained from DrugBank
(Accession DB00073). The rituximab heavy chain (HC) and light chain (LC) genes were fused to
the Pathogenesis-related protein (PR1a) signal peptide sequence (UniProtKB/Swiss-Prot: P08299.1).
Rituximab HC and LC genes were codon optimized for plant expression using the Nicotiana tabacum
codon usage table (DNA2.0, Menlo Park, CA, USA) and independently cloned into proprietary
plant viral-based expression vectors (iBio Inc., New York, NY, USA). Vectors were then mobilized in
Agrobacterium tumefaciens strain GV3101 for transient expression in Nicotiana benthamiana.
4.2. Expression and Extraction
Agrobacterium clones harboring HC and LC expression vectors were grown individually in culture
flasks containing Luria-Bertani (LB) medium supplemented with 50 mg/L kanamycin, 50 mg/L
gentamycin and 25 mg/L rifampicin at 28 ◦C with agitation of 225 rpm. Cultures reaching an
OD600 nm of ~3.0 were collected and diluted in 2 mM MES (2-(N-morpholino)ethanesulfonic acid)
to a final OD600 nm of 0.05 for each culture. N. benthamiana four-week old plants, hydroponically
grown under red/blue LED (Light-Emitting Diode) light were vacuum infiltrated with Agrobacterium
culture, as described previously [46], along with varying concentrations of kifunensine mixed in the
infiltration solution. Kifunensine concentrations used for infiltrations included a ‘higher range’ at
5 µM, 2.5 µM, and 1.5 µM; ‘medium range’ 1.25 µM, 0.75 µM, and 0.375 µM; and ‘lower range’ 0.25 µM,
0.125 µM, and 0.0625 µM. Control infiltration was carried out without kifunensine. Each infiltration
was carried out with 60-plant batches and kifunensine was freshly prepared for each infiltration.
Agro-infiltrated plants were then incubated under constant LED light at ~22 ◦C with relative humidity
of ~ 50% for rituximab production. After seven days post-infiltration (dpi), plants were harvested, and
proteins extracted. Agrobacterium infiltrated N. benthamiana biomass was mechanically homogenized
in three volumes (Weight/Volume) of extraction buffer (50 mM sodium phosphate, 150 mM sodium
chloride, 60 mM ascorbic acid, 5 mM EDTA, 1 mM PMSF (phenylmethylsulfonyl fluoride), pH 5.5)
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using a Waring blender at maximum speed for one minute. Primary clarification was achieved by
centrifugation at 14,000×g for 20 min at 4 ◦C. To determine the concentration of the rituximab in the
samples, the supernatant was harvested and a 4 µL sample was analyzed with the BLItz system using
protein A sensors (Pall ForteBio, Menlo Park, CA, USA). After data acquisition, the concentration of
rituximab in the extracts was calculated based on a rituximab reference standard.
4.3. Purification and SDS-PAGE Analysis
Rituximab purification was carried out as described earlier [45]. Antibody samples were analyzed
on a 4–12% Bis-Tris gradient NuPAGE™ gel under reducing conditions according to the manufacturer’s
protocol (Life Technologies, Carlsbad, CA, USA).
4.4. Intact Protein Analysis
Purified rituximab samples were exchanged into 50 mM ammonium bicarbonate, pH 8.0 buffer
and adjusted to 1 mg/mL. A 5 µL aliquot was injected into a BEH C4 column 300 Å, 1.7 µm
2.1 mm × 100 mm (Waters Corporation, Milford, MA, USA) equilibrated with 0.1% (v/v) formic
acid in water at a flow rate of 200 µL/min. Proteins were eluted using a gradient of 2–85% acetonitrile
(v/v) over the course of 30 min. A blank solution using acetonitrile was utilized between each
sample to avoid peak carry-over between runs. The mass spectrometer was calibrated using PPG
(polypropylene glycol) positive ion calibration solution from SCIEX (AB SCIEX LLC, Framingham,
MA, USA). The eluted proteins were introduced into the mass spectrometer and analyzed using the
mass spectrometer in the positive ion mode with the following settings: Intact protein mode, scan
range 1500–4000 m/z (mass to charge ratio), Accumulation Time 0.5 s, GS1 (Ion Source Gas 1) = 45,
GS2 (Ion Source Gas 2) = 50, CUR (curtain gas) = 30, source temperature = 400 ◦C, DP (declustering
potential)= 225V, CAD (collisionally activated dissociation)= 6, CE (collision energy) = 15V and ISVF
(IonSpray Voltage Floating) = 4800. The raw data of intact protein analysis were processed using the
software Unidec (University of Oxford, Oxford, UK) with subtract curved of, Gaussian smoothing of 5,
bin every 1, peak FWHM (Full width at half maximum) of 2 and peak detection threshold of 0.1.
4.5. Glycopeptide Profiling
The purified rituximab samples were analyzed with LC/MS/MS based peptide mapping
method as previously described [45]. The glycopeptides were identified manually by screening the
N-Acetylglucosamine residue reporter ion (m/z = 204.0794) in MS/MS ion fragmentation spectrum
of the second run. Glycopeptide candidates were further filtered manually by matching fragment
ions with predicted glycopeptide sequences. The retention time of a positive candidate was used
to determine the retention time for all other glycopeptides in the results of the first run. All other
glycopeptides were determined by matching the observed molecular weights with predicted ones
in the results of the first run. The relative abundance of each glycopeptide was calculated by its
corresponding peak areas of extracted ion chromatograph.
4.6. Cell Lines and Cell Culture Conditions
The hereditary spherocytosis cell line Wil2-S was obtained from the American Type Culture
Collection (ATCC, Manassas, VA, USA). Wil2-S cells were cultured in RPMI (Roswell Park Memorial
Institute medium, Corning, NY, USA) media supplemented with 10% fetal bovine serum (VWR, Radnor,
PA, USA). Cells were seeded in culture flasks at a density of 1×105 cells/mL, incubated at 37 ◦C with 7%
CO2, and sub-cultured when the cell density reached approximately 1.5–2×106 cells/mL.
4.7. CD20 Binding Assay
The binding of plant-made rituximab to target cells (Wil2-S) was determined with flow cytometry
analysis using a Becton Dickinson Accuri C6 flow cytometer. Wil2-S lymphoma cells at 1×106 cells/mL
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were incubated with different concentrations of Rituxan® (Genentech, South San Francisco, CA, USA),
or plant-made rituximab treated either with 5 µM, 0.25 µM or no kifunensine for 45 min at 4 ◦C.
Cells were washed and incubated with FITC conjugated anti-human IgG Fc (BioLegend, San Diego,
CA, USA) in phosphate-buffered saline (PBS) with 2% fetal bovine serum (FBS). FITC-labeled
Mouse IgG2a, kappa (BioLegend, San Diego, CA, USA) was used as an isotype control. Cells were
analyzed by flow cytometry after briefly washing them with PBS containing 2% FBS. 7-AAD
(7-amino-actinomycin D) exclusion dye was used for the quantification and segregation of dead
cells in each sample. Cell Quest data acquisition software (BD Biosciences, San Jose, CA, USA) and
Flowjo FACS (Fluorescence-activated cell sorting) analysis software (Tree Star Inc., Ashland, OR, USA)
were used to derive data plots. Cell labelling and Flowjo FACS analysis was as described earlier [45].
4.8. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Assay
The ADCC reporter assay was performed using Wil2-S cells as targets along with Jurkat-CD16
reporter cell lines. Two reporter cell lines stably expressing the FcγRIIIa receptor, V158 (high affinity)
or F158 (low affinity) variants (Promega, Madison, WI, USA) were used. Wil2-S cells were plated in a
96-well white bottom assay plate at 5000 cells per well. Serial dilutions of test antibodies were added
to the plates containing the target cells and incubated at 4 ◦C for 15 min to allow opsonization.
Jurkat-CD16 reporter cells were then added to assay plates already containing Wil2-S cells and
antibodies. The final concentration of antibodies ranged from 2 to 0.0003 µg/mL following several
3-fold dilutions. The effector:target cell ratio was 10:1. After a 6 h. incubation at 37 ◦C, One-Glo™
Luciferase Assay Reagent (Promega, Madison, WI, USA) was added and luminescence was determined
using a Gen5 microplate reader. Samples and controls were tested in triplicate, and the mean reporter
signals of sample dilutions in Relative Luminescence Units (RLU) were plotted against the antibody
concentration. Antibody independent cellular cytotoxicity (AICC) was measured in wells containing
target and effector cells without antibodies. GraphPad prism software (GraphPad, La Jolla, CA, USA)
was used to plot normalized RLU versus Log10. The half maximal effective concentration (EC50) values
of plant-made rituximab and Fc variants were derived as dose responses obtained from non-linear
regression curves. Fold of induction was calculated by taking the ratio of background subtracted
induced RLU and background subtracted untreated control.
5. Conclusions
Glyco-engineering methods represent promising means to enhance biological activities of
therapeutic glycoproteins. In this study, we evaluated the effectiveness of α-mannosidase-I inhibitor
kifunensine, to modulate the metabolic pathway of the Nicotiana benthamiana transient expression
platform. We demonstrated that 0.375 µM of kifunensine applied to the infiltration solution
was sufficient to block the trimming of Man9 and Man8 oligosaccharides and resulted in the
production of completely afucosylated rituximab, an anti-CD20 antibody. Oligomannose rituximab
glycoforms did not possess any plant-specific α(1,3)-fucose and β(1,2)-xylose and showed an increase
antibody-dependent cell-mediated cytotoxicity (ADCC) when compared to Rituxan® or rituximab
with plant complex-glycans. In addition, kifunensine modulated the plant N-glycosylation pathway
without affecting plant growth or protein expression. Incorporating kifunensine into the N. benthamiana
transient expression system, a cost-effective and scalable expression system, provides a simple
alternative to the generation of transgenic plants, both expensive and time-consuming. This technology
is applicable to many therapeutic glycoproteins for which oligomannose glycosylation offers a
therapeutic advance, like the anti-cancer antibody rituximab.
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